LGND · CIK 886163

What Ligand Pharmaceuticals, Inc. told the SEC could break it.

1 self-disclosed vulnerability, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.

A limited set so far, we surface every cited disclosure we’ve extracted for LGND. More may follow as additional filings are processed.

In its own words

What could break it.

Sole-source dependency

Captisol sourced from a single supplier (Hovione, two sites)high
Ligand's Captisol franchise — both its direct Captisol material sales and the broader Captisol-enabled partner products it earns royalties on — depends on a single supplier, Hovione, producing from two sites (Lisbon, Portugal and Cork, Ireland). If Hovione could not supply requested amounts from each site and Ligand's safety stocks were depleted, Ligand would be unable to continue deriving Captisol revenue until it qualified an alternative source, a single point of failure for a core revenue line.
“We obtain Captisol primarily from two sites related to a single supplier, Hovione. If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source,”
SEC filing →As of 2026

The hidden graph

Who it depends on, and who depends on it.

Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.

Its customers

CASI Pharmaceuticals, Inc.
“Acrotech Biopharma has marketing rights worldwide excluding China, and CASI Pharmaceuticals has marketing rights in China. We receive a 20% royalty on global net sales of the Captisol-enabled melphalan product and revenue from Captisol material sales.”
Cited →
Travere Therapeutics, Inc.
“Pursuant to the Ligand License Agreement, we are obligated to pay Ligand (and Bristol-Myers Squibb Company ("BMS")) an escalating royalty between 15% and 17% of net sales of sparsentan, with payments due quarterly.”
Cited →
Viking Therapeutics, Inc.
“A summary of the Master License Agreement can be found under the heading “Master License Agreement with Ligand” under Part I, “Item 1. Business” of this Annual Report on Form 10-K.”
Cited →

In the MyPRIA app, this is checked against the companies you actually own.

← World Watch

What could break it.

Sole-source dependency

Captisol sourced from a single supplier (Hovione, two sites)high
Ligand's Captisol franchise — both its direct Captisol material sales and the broader Captisol-enabled partner products it earns royalties on — depends on a single supplier, Hovione, producing from two sites (Lisbon, Portugal and Cork, Ireland). If Hovione could not supply requested amounts from each site and Ligand's safety stocks were depleted, Ligand would be unable to continue deriving Captisol revenue until it qualified an alternative source, a single point of failure for a core revenue line.
“We obtain Captisol primarily from two sites related to a single supplier, Hovione. If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source,”
SEC filing →As of 2026

Who it depends on, and who depends on it.

Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.

Its customers

CASI Pharmaceuticals, Inc.
“Acrotech Biopharma has marketing rights worldwide excluding China, and CASI Pharmaceuticals has marketing rights in China. We receive a 20% royalty on global net sales of the Captisol-enabled melphalan product and revenue from Captisol material sales.”
Cited →
Travere Therapeutics, Inc.
“Pursuant to the Ligand License Agreement, we are obligated to pay Ligand (and Bristol-Myers Squibb Company ("BMS")) an escalating royalty between 15% and 17% of net sales of sparsentan, with payments due quarterly.”
Cited →
Viking Therapeutics, Inc.
“A summary of the Master License Agreement can be found under the heading “Master License Agreement with Ligand” under Part I, “Item 1. Business” of this Annual Report on Form 10-K.”
Cited →